Position Paper: Are We Abandoning IQ and OQ? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Position Paper: Are We Abandoning IQ and OQ?
The author explores differences between two qualification documents, the draft guidance from FDA "Process Validation: General Principles and Practice" and the ASTM E2500-7 standard "Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment."


Pharmaceutical Technology
Volume 33, Issue 11

Another program promulgated by FDA, was the system approach to facility inspection. With each inspection, which is also predicated on risk, FDA would concentrate on different quality systems. The frequency and depth of inspections would be determined by conclusions of previous establishment inspection report (EIR), the Form 483 observations, and/or warning letters a firm may have received in the past. One of the systems is facility and equipment. After reviewing the FDA validation guidance, it is apparent that there will not be an immediate surge toward adapting the ASTM standard as common practice. The risk, in this author's mind, is much too high.


Table I: Document similarities
Even though FDA has not abandoned the concept of qualification, it states that the verification is to be achieved through qualification. In the ASTM standard, the word qualification is not used and instead we find just the word verification. In this author's mind, verification is one step removed from qualification, and these words are not necessarily interchangeable.

Definitions and summary

Verification. The act of reviewing, inspecting, testing, etc., to establish and document that a product, service, or system meets the regulatory, standard, or specification requirements.


Table II: Document differences
Qualification. The process of certifying that a certain product has passed performance and quality-assurance tests or qualification requirements stipulated in regulations such as a building code and nationally accredited test standards, or that it complies with a set of regulations governing quality and minimum performance requirements.


Table III: ASTM E2500 and FDA draft guidance topic comparisons.
As a summary, the Table II provides some simple comparisons regarding the major similarities and differences between these two documents. Though they may seem to be quite similar, the similarities are in word only, but not necessarily in content. The differences between these documents are even more striking. The FDA participated in the generation and review of not only the ASTM standard, but also the ISPE commissioning and qualification (C&Q) guide. In the future and once either the rewrite or the new Guide number 12 is complete, FDA will once again be called upon to give its opinion and review. Table III shows a comparison of major topics covered in both ASTM E2500-07 and the FDA draft guidance document.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here